Description: Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Home Page: silopharma.com
SILO Technical Analysis
677 N. Washington Boulevard
Sarasota,
FL
34236
United States
Phone:
718 400 9031
Officers
| Name | Title |
|---|---|
| Mr. Eric Weisblum | Chairman, President & CEO |
| Mr. Daniel E. Ryweck | Chief Financial Officer |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5522 |
| Price-to-Sales TTM: | 51.9399 |
| IPO Date: | 2014-05-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |